Vista Pharmaceuticals News

Vista Pharmaceuticals Reports Q3 FY26 Loss of ₹231.94 Lakhs

Vista Pharmaceuticals posted a net loss of ₹231.94 lakhs for Q3 FY26, widening from ₹132.23 lakhs in Q3 FY25. Revenue declined to ₹241.82 lakhs from ₹255.50 lakhs year-on-year.

Vista Pharmaceuticals Reports Widened Loss of Rs 362.21 Lakhs in Q2 FY2025

Vista Pharmaceuticals reported a loss before tax of Rs 362.21 lakhs for the quarter ended September 30, 2025, significantly higher than Rs 125.20 lakhs loss in the corresponding quarter of the previous year, with revenue declining to Rs 165.49 lakhs from Rs 250.17 lakhs. The company recognized a provision for Expected Credit Loss of Rs 205.43 lakhs against long-pending trade receivables and issued 10,249,998 Convertible Share Warrants, receiving Rs 307.50 lakhs as part payment.

Vista Pharmaceuticals Reports Quarterly Loss, Approves Director Reappointments and AGM Schedule

Vista Pharmaceuticals Limited approved unaudited financial results for the quarter ended June 30, 2025, showing a net loss of Rs. 129.04 lakhs compared to Rs. 85.70 lakhs loss in the same quarter last year. Revenue declined to Rs. 151.88 lakhs from Rs. 179.50 lakhs year-over-year. The board recommended reappointment of two directors retiring by rotation and approved reappointment of three key executives - Managing Director Murali Meraga, and Whole-time Directors Pavan Sathvik Gilaka and Dhananjaya Alli - for three-year terms starting October 19, 2025. The company scheduled its 34th Annual General Meeting for September 30, 2025, via video conferencing, with share transfer books closing from September 24-30, 2025.